The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Familial nonmedullary thyroid cancer (FNMTC) is relatively common but its predisposing genetic alteration is unclear. As the somatic T1799A BRAF mutation is highly prevalent in papillary thyroid cancer, the aim was to test whether this mutation was a susceptibility mutation for FNMTC. Subjects and methods: The T1799A BRAF mutation as a possible germline mutation was examined in 40 subjects from 23 families with a history of FNMTC. Direct DNA sequencing was performed on white blood cell DNA samples to analyse the mutation status. Results: No T1799A BRAF mutation was found in this group of subjects as germline mutation. Conclusion: The T1799A BRAF mutation is not a germline mutation or susceptibility genetic event for FNMTC.

Original languageEnglish (US)
Pages (from-to)263-266
Number of pages4
JournalClinical Endocrinology
Volume63
Issue number3
DOIs
StatePublished - Sep 1 2005

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'The T1799A BRAF mutation is not a germline mutation in familial nonmedullary thyroid cancer'. Together they form a unique fingerprint.

Cite this